Maridebart cafraglutide clinical trials
5 indexed studies · 3 currently recruiting
- RecruitingPHASE3
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
This study is testing a new medicine, Maridebart Cafraglutide, for adults with sleep apnea who use a CPAP machine and are also overweight or have obesity. We want to see if the medicine helps improve their sleep apnea and is safe to use over 52 weeks.
For: Obesity · Obstructive Sleep ApneaUnited States · Australia · Brazil - Active not recruitingPHASE3
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
This study is looking into a new medication called maridebart cafraglutide. It's for adults with type 2 diabetes who are overweight or have obesity. The main goal is to see if this new medicine helps with weight loss more than a dummy treatment.
For: Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightUnited States · Argentina · Bulgaria - RecruitingPHASE3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Researchers are studying a new drug called Maridebart Cafraglutide to see if it can help people with heart disease and who are overweight or obese. The goal is to find out if this drug can lower the risk of heart attacks, strokes, and other serious heart problems.
For: Atherosclerotic Cardiovascular Disease · Overweight · ObesityUnited States · Argentina · Australia - Active not recruitingPHASE3
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
This study is looking at a new medicine called Maridebart Cafraglutide to see if it helps adults who are overweight or have obesity lose weight. It compares the medicine to a dummy treatment (placebo) to find out if it's more effective.
For: ObesityUnited States · Argentina · Australia - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
For: Heart Failure With Preserved Ejection Fraction · Heart Failure With Mildly Reduced Ejection Fraction · ObesityUnited States · Argentina · Australia